𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Acetylcholine-induced vasorelaxation in portal hypertensive rats

✍ Scribed by Peter P. Michielsen; Guy E. Boeckxstaens; Stanislas U. Sys; Arnold G. Herman; Paul A. Pelckmans; Wladimiro Jiménez


Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
372 KB
Volume
22
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Circulatory changes induced by portal ve
✍ Dr. Samuel S. Lee; Kaj Johansen; Didier Lebrec 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 614 KB

We studied the hemodynamics in four groups of rats with combinations of mesenteric hypertension and portal diversion. Operations created three groups with mesenteric hypertension and different degrees of portal venous diversion: mesenteric vein stenosis, portal vein stenosis and end-to-side portacav

The role of portal pressure in the sever
✍ Beatriz Castañeda; Wilma Debernardi-Venon; Juan-Carlos Bandi; Victoria Andreu; S 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB 👁 1 views

The aim of this study was to investigate the role of portal hypertension determining the severity of bleeding in portal hypertensive rats. The effects of section of branches of the ileocolic vein were studied in sham-operated (SO), partial portal vein-ligated (PPVL), and common bile duct-ligated (CB

Increased angiogenesis in portal hyperte
✍ Lazar T. Sumanovski; Edouard Battegay; Michael Stumm; Maaike van der Kooij; Corn 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 560 KB

Systemic and especially splanchnic arterial vasodilation accompany chronic portal hypertension. Different soluble mediators causing this vasodilation have been proposed, the strongest evidence being for nitric oxide (NO). No data exist if structural vascular changes may partly account for this vasod

Long-term octreotide treatment prevents
✍ C C Sieber; F Lee; R J Groszmann 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 210 KB

Chronically portal-hypertensive rats show in vitro vascular hyporeactivity in large part mediated by the endothelium-derived vasodilator nitric oxide. We tested whether long-term octreotide treatment (15 micrograms/kg subcutaneously in 5% D/W, 8-hourly) corrects the in vitro vascular hyporeactivity.